Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens

Calvin Q. Pan,Ming‐Hui Li,Wei Yi,Lu Zhang,Yao Lu,Hong‐Xiao Hao,Gang Wan,Wei‐Hua Cao,Xing‐Yue Wang,Chong‐Ping Ran,Ge Shen,Shu‐Ling Wu,Min Chang,Yuan‐Jiao Gao,Yao Xie

DOI: https://doi.org/10.1111/liv.14801

IF: 8.754

2021-02-16

Liver International

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background &amp; Aims</h3><p>Nucleotides with add‐on interferon treatment (NUC‐IFN) provide significantly higher rates of hepatitis B surface antigen (HBsAg) loss in patients with chronic hepatitis B (CHB). This study aimed to investigate the sustainability of HBsAg loss and the prevention of clinical relapse.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Patients with CHB who achieved HBsAg loss and HBV DNA levels &lt;20 IU/mL after IFN or NUC‐IFN therapy were enrolled and followed up for 96 weeks. The primary outcome was HBsAg negativity without viremia at week 96. Secondary outcomes included virological or clinical relapse and predictors of relapse.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>420 patients were included in intention‐to‐treat analysis with 290 and 130 in the IFN and NUC‐IFN groups, respectively. At week 96, the intention‐to‐treat analyss revealed similar outcomes between groups, including HBsAg seroreversion (24.83% vs. 23.08%, <i>p</i>=0.70), viremia (16.90% vs. 13.08%, <i>p</i>=0.32) and clinical relapse (11.38% vs. 10.00%, <i>p</i>=0.68); the per‐protocol analyses also showed HBsAg seroreversion, viremia and clinical relapse in IFN group (15.50%, 6.59% and 0.39&amp;) did not differ from those in NUC‐IFN group (15.25%, 4.24% and 0.85%, p&gt;0.05). These outcomes were similar between patients who received entecavir and those who received telbivudine/lamivudine/adefovir before the combination therapy. In NUC‐IFN‐treated patients, fibrosis regression was observed at week 96. Baseline HBsAb negativity was independent predictors of HBsAg sero‐reversion and recurrence of viremia in IFN treated group. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>NUC‐IFN and IFN therapies are equally effective in achieving sustained functional cure and fibrosis regression. (ClinicalTrials.gov, Number NCT02336399).</p></section>

gastroenterology & hepatology

What problem does this paper attempt to address?

### The Problem the Paper Attempts to Solve

This paper aims to investigate the persistence of hepatitis B surface antigen (HBsAg) negativity and the prevention of clinical relapse within 96 weeks after discontinuation of treatment in chronic hepatitis B (CHB) patients who achieved HBsAg negativity and hepatitis B virus (HBV) DNA levels below the detection limit (<20 IU/mL) following treatment with interferon (IFN) or nucleos(t)ide analogs combined with interferon (NUC-IFN).

Specifically, the primary objective of the study is to evaluate the proportion of patients who are HBsAg negative and without viremia at 96 weeks. Secondary objectives include the incidence of virological or clinical relapse and the predictive factors for relapse. Additionally, the study explores whether baseline HBs antibody (HBsAb) negativity is an independent predictor of HBsAg seroconversion and viremia relapse in the IFN treatment group. The study also found that fibrosis reversal was observed at 96 weeks in patients treated with NUC-IFN.